Kintara Therapeutics Inc. (NASDAQ: KTRA) jumped 9% after announcing that its CEO SaiidZarrabian is scheduled to make a corporate overview presentation during the 14th Annual LD Micro Main Event conference that will be held between October 12 and 14, 2021, in Los Angeles at the Luxe Sunset Bel-Air. Zarrabian is expected to deliver the corporate overview on October 12 and 5:00 PM ET.
The company recently released topline results from its newly-diagnosed adjuvant cohort of the open-label second phase clinical trials being carried out in Houston, Texas, at the MD Anderson Cancer Centre. The second phase study was a biomarker0driven, two-arm trial evaluating VAL-083 in treating glioblastoma multiforme patients having methyguanine DNA-Methyltransferase gene’s unmethylated promoter.
In July, the company reported topline data from its recurrent GBM cohort of the trial, which offered vital efficacy and safety data supporting continued VAL-083 evaluation for GBM treatment. The company observed a PFS of 10 months and median overall survival of 16.5 months in the 36 evaluable subjects. So, in the coming months, KTRA is worth watching.
Market Reaction:
On Monday, KTRA stock rose 9.04% at $0.8348 with more than 3 million shares, compared to its average volume of 889k shares. The stock has moved within a range of $0.7656 – 0.8590 after opening the trade at $0.7656.
